WO2000058488A3 - Delivery of functional protein sequences by translocating polypeptides - Google Patents

Delivery of functional protein sequences by translocating polypeptides Download PDF

Info

Publication number
WO2000058488A3
WO2000058488A3 PCT/US2000/008571 US0008571W WO0058488A3 WO 2000058488 A3 WO2000058488 A3 WO 2000058488A3 US 0008571 W US0008571 W US 0008571W WO 0058488 A3 WO0058488 A3 WO 0058488A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
culture
target gene
delivery
contacting
Prior art date
Application number
PCT/US2000/008571
Other languages
French (fr)
Other versions
WO2000058488A2 (en
Inventor
Brian Dalby
Robert P Bennett
Original Assignee
Invitrogen Corp
Brian Dalby
Robert P Bennett
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invitrogen Corp, Brian Dalby, Robert P Bennett filed Critical Invitrogen Corp
Priority to JP2000608767A priority Critical patent/JP2002539839A/en
Priority to EP00919948A priority patent/EP1165819A2/en
Priority to AU40555/00A priority patent/AU775001B2/en
Priority to US09/937,837 priority patent/US6773920B1/en
Priority to CA002368998A priority patent/CA2368998A1/en
Publication of WO2000058488A2 publication Critical patent/WO2000058488A2/en
Publication of WO2000058488A3 publication Critical patent/WO2000058488A3/en
Priority to US10/865,538 priority patent/US20050208657A1/en
Priority to AU2004220829A priority patent/AU2004220829A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides methods for modulating a cellular process by contacting a cell in culture with a cell process-modifying molecule attached to a translocating polypeptide. For example, in one embodiment, a cell in culture is transfected with a target gene by contacting the cell in culture with a polynucleotide (that contains the target gene) attached to a translocating polypeptide. In another embodiment, expression of a target gene product in a cell in culture that contains a target gene under control of one or more regulatory elements is modulated by contacting the cell in culture with one or more regulatory agents attached to a translocating polypeptide. The one or more regulatory agents are translocated into the cell in culture and interact therein with the one or more regulatory elements to modulate expression of the target gene product by the cell.
PCT/US2000/008571 1999-03-31 2000-03-31 Delivery of functional protein sequences by translocating polypeptides WO2000058488A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2000608767A JP2002539839A (en) 1999-03-31 2000-03-31 Delivery of functional protein sequences by translocating polypeptides
EP00919948A EP1165819A2 (en) 1999-03-31 2000-03-31 Delivery of functional protein sequences by translocating polypeptides
AU40555/00A AU775001B2 (en) 1999-03-31 2000-03-31 Delivery of functional protein sequences by translocating polypeptides
US09/937,837 US6773920B1 (en) 1999-03-31 2000-03-31 Delivery of functional protein sequences by translocating polypeptides
CA002368998A CA2368998A1 (en) 1999-03-31 2000-03-31 Delivery of functional protein sequences by translocating polypeptides
US10/865,538 US20050208657A1 (en) 1999-03-31 2004-06-09 Delivery of functional protein sequences by translocating polypeptides
AU2004220829A AU2004220829A1 (en) 1999-03-31 2004-10-15 Delivery of functional protein sequences by translocating polypeptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12746799P 1999-03-31 1999-03-31
US60/127,467 1999-03-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/865,538 Continuation US20050208657A1 (en) 1999-03-31 2004-06-09 Delivery of functional protein sequences by translocating polypeptides

Publications (2)

Publication Number Publication Date
WO2000058488A2 WO2000058488A2 (en) 2000-10-05
WO2000058488A3 true WO2000058488A3 (en) 2001-01-18

Family

ID=22430280

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/008571 WO2000058488A2 (en) 1999-03-31 2000-03-31 Delivery of functional protein sequences by translocating polypeptides

Country Status (5)

Country Link
EP (1) EP1165819A2 (en)
JP (2) JP2002539839A (en)
AU (2) AU775001B2 (en)
CA (1) CA2368998A1 (en)
WO (1) WO2000058488A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8952133B2 (en) 2003-10-24 2015-02-10 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissue
US9358300B2 (en) 1998-11-12 2016-06-07 Life Technologies Corporation Transfection reagents

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6989434B1 (en) 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
DE19933492B4 (en) 1999-07-16 2008-01-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Conjugate for the mediation of a cell-, compartment- or membrane-specific transport of active substances, process for its preparation and its use
CA2396149A1 (en) * 2000-01-07 2001-07-12 Artemis Pharmaceuticals Gmbh Transduction of recombinases for inducible gene targeting
AU2001288955A1 (en) * 2000-09-07 2002-03-22 Vanderbilt University Genome engineering by cell-permeable dna site-specific recombinases
FR2816845B1 (en) 2000-11-20 2006-10-20 Centre Nat Rech Scient TRANSPORT VECTORS THROUGH A GREEN JUNCTION EPITHELIUM
AU2002238376B2 (en) * 2001-01-10 2007-05-10 Lonza Cologne Gmbh Modular transfection systems based on nucleoprotein filaments
US7364750B2 (en) 2001-04-30 2008-04-29 The University Of British Columbia Autogene nucleic acids encoding a secretable RNA polymerase
EP1495124A2 (en) * 2002-04-17 2005-01-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
EP1354952A1 (en) * 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
EP1354953A1 (en) * 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
ITMI20030821A1 (en) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And CHEMICAL POLYPEPTIDES AND THEIR USE.
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
JP4838722B2 (en) * 2003-10-24 2011-12-14 ゲンシア コーポレーション Methods for delivering polynucleotides and compositions for delivery
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US20050209147A1 (en) * 2004-01-16 2005-09-22 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of RhoA signaling
GB0515115D0 (en) * 2005-07-22 2005-08-31 Isogenica Ltd Peptide characterisation
DE102008051708A1 (en) * 2008-10-06 2010-04-08 Universität Tübingen Site-specific recombination for gene activation in genetic systems
EP2612918A1 (en) 2012-01-06 2013-07-10 BASF Plant Science Company GmbH In planta recombination
JP6744225B2 (en) * 2014-02-14 2020-08-19 シンヴィヴォ コーポレイション Hybrid proteins and their use
WO2016011203A1 (en) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005265A1 (en) * 1995-07-28 1997-02-13 Marie Curie Cancer Care Transport proteins and their uses
WO1998032866A1 (en) * 1997-01-23 1998-07-30 Marie Curie Cancer Care Fusion proteins for intracellular and intercellular transport and their uses
WO1999005302A1 (en) * 1997-07-24 1999-02-04 The Perkin-Elmer Corporation Conjugates of transporter peptides and nucleic acid analogs, and their use
WO1999011809A1 (en) * 1997-09-02 1999-03-11 Imperial College Innovations Limited Conjugates that contain the homeodomain of antennapedia
WO1999024559A2 (en) * 1997-11-11 1999-05-20 Actinova Limited Nuclear targeting by means of streptococcal protein h

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU727531B2 (en) * 1995-07-25 2000-12-14 Crucell Holland B.V. Methods and means for targeted gene delivery
AU8597098A (en) * 1997-07-28 1999-02-16 Minnesota Mining And Manufacturing Company Spore germination media

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005265A1 (en) * 1995-07-28 1997-02-13 Marie Curie Cancer Care Transport proteins and their uses
WO1998032866A1 (en) * 1997-01-23 1998-07-30 Marie Curie Cancer Care Fusion proteins for intracellular and intercellular transport and their uses
WO1999005302A1 (en) * 1997-07-24 1999-02-04 The Perkin-Elmer Corporation Conjugates of transporter peptides and nucleic acid analogs, and their use
WO1999011809A1 (en) * 1997-09-02 1999-03-11 Imperial College Innovations Limited Conjugates that contain the homeodomain of antennapedia
WO1999024559A2 (en) * 1997-11-11 1999-05-20 Actinova Limited Nuclear targeting by means of streptococcal protein h

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BONFANTI M ET AL: "p21 WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth", CANCER RESEARCH,US,AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, vol. 57, 15 April 1997 (1997-04-15), pages 1442 - 1446, XP002087115, ISSN: 0008-5472 *
CHEN XIAOZHUO ET AL: "A SELF-INITIATING EUKARYOTIC TRANSIENT GENE EXPRESSION SYSTEM BASED ON COTRANSFECTION OF BACTERIOPHAGE T7 TNA POLYMERASE AND DNA VECTORS CONTAINING A T7 AUTOGENE", NUCLEIC ACIDS RESEARCH,GB,OXFORD UNIVERSITY PRESS, SURREY, vol. 22, no. 11, 11 June 1994 (1994-06-11), pages 2114 - 2120, XP002029322, ISSN: 0305-1048 *
ELLIOTT G ET AL: "Intercellular trafficking of VP22 -GFP fusion proteins", GENE THERAPY,GB,MACMILLAN PRESS LTD., BASINGSTOKE, vol. 6, no. 1, January 1999 (1999-01-01), pages 149 - 151, XP002119414, ISSN: 0969-7128 *
FRITZ J D ET AL: "GENE TRANSFER INTO MAMMALIAN CELLS USING HISTONE-CONDENSED PLASMID DNA", HUMAN GENE THERAPY,XX,XX, vol. 7, 1 August 1996 (1996-08-01), pages 1395 - 1404, XP002058321, ISSN: 1043-0342 *
INVITROGEN: "Voyager(TM) - The power of Translocation", INVITROGEN CATALOGUE,XX,XX, vol. 6, no. 1, February 1999 (1999-02-01), pages 6, XP002140132 *
LANGEL U ET AL: "Cell penetrating PNA constructs", JOURNAL OF NEUROCHEMISTRY,US,NEW YORK, NY, vol. 69, no. SUPPL, 20 July 1997 (1997-07-20), pages S260, XP002088767, ISSN: 0022-3042 *
MURPHY A L ET AL: "Catch VP22: the hitch-hiker's ride to gene therapy?", GENE THERAPY,GB,MACMILLAN PRESS LTD., BASINGSTOKE, vol. 6, no. 1, January 1999 (1999-01-01), pages 4 - 5, XP002119415, ISSN: 0969-7128 *
NIIDOME TAKURO ET AL: "Binding of cationic alpha-helical peptides to plasmid DNA and their gene transfer abilities into cells.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 24, 1997, pages 15307 - 15312, XP002149406, ISSN: 0021-9258 *
PROCHIANTZ A: "Getting hydrophilic compounds into cells: lessons from homeopeptides", CURRENT OPINION IN NEUROBIOLOGY,GB,LONDON, vol. 6, no. 5, 1 October 1996 (1996-10-01), pages 629 - 634, XP002087113, ISSN: 0959-4388 *
PROCHIANTZ A: "Peptide nucleic acid smugglers", NATURE BIOTECHNOLOGY,US,NATURE PUBLISHING, vol. 16, 1 September 1998 (1998-09-01), pages 819 - 820, XP002088768, ISSN: 1087-0156 *
WEN W ET AL: "IDENTIFICATION OF A SIGNAL FOR RAPID EXPORT OF PROTEINS FROM THE NUCLEUS", CELL,US,CELL PRESS, CAMBRIDGE, NA, vol. 82, 11 August 1995 (1995-08-11), pages 463 - 473, XP002912310, ISSN: 0092-8674 *
ZAITSEV S V ET AL: "H1 and HMG17 extracted from calf thymus nuclei are efficient DNA carriers in gene transfer.", GENE THERAPY, vol. 4, no. 6, 1997, pages 586 - 592, XP000952517, ISSN: 0969-7128 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9358300B2 (en) 1998-11-12 2016-06-07 Life Technologies Corporation Transfection reagents
US8952133B2 (en) 2003-10-24 2015-02-10 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissue

Also Published As

Publication number Publication date
CA2368998A1 (en) 2000-10-05
JP2002539839A (en) 2002-11-26
WO2000058488A2 (en) 2000-10-05
AU775001B2 (en) 2004-07-15
AU4055500A (en) 2000-10-16
AU2004220829A1 (en) 2004-11-18
JP2005323619A (en) 2005-11-24
EP1165819A2 (en) 2002-01-02

Similar Documents

Publication Publication Date Title
WO2000058488A3 (en) Delivery of functional protein sequences by translocating polypeptides
BR9506058A (en) Sequence of polynucleotide and dna vector of host cell dna process to produce a protocaderine polypeptide polypeptide antibody substance hybridoma cell lineage and process to modulate protocaderin binding activity
EP0770129A4 (en) Zinc finger protein derivatives and methods therefor
DE69434663D1 (en) NUCLEOTIDE SEQUENCES FOR CONTROLLING THE EXPRESSION OF DNA SEQUENCES IN A CELLULAR HOST
IE883612L (en) Vectors and compounds for direct expression of activated human protein c
AU7599500A (en) Novel gl50 molecules and uses therefor
WO2003027266A3 (en) Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
WO1994018332A3 (en) Anthrax toxin fusion proteins and uses thereof
AU4427389A (en) Peptides and antibodies that inhibit integrin-ligand binding
IL148021A0 (en) Novel b7-4 molecules and uses therefor
WO1997033995A3 (en) Extracellular matrix signalling molecules
EP0523140A4 (en) Reagents and methods for modulating gene expression through rna mimicry
WO1996004373A3 (en) Recombinant production of biologically active peptides and proteins
FI965031A (en) The fungus in which the AreA gene has been modified and the areA gene from Aspergillus oryzae
AU1860395A (en) Novel human beta 2 integrin alpha subunit
EP1074618A3 (en) Cadherin materials and methods
WO2002002751A3 (en) Alteration of cell membrane
WO2001055210A3 (en) Human cyr61
WO1990014426A3 (en) Saf polypeptide, gene, promoter and use for expression in streptomyces
DE59712554D1 (en) RECOMBINANT EXPRESSION OF S-LAYER PROTEINS
WO2001009293A3 (en) Mammalian adhesion protease peptides
WO1998054344A3 (en) Modulators of morphogen expression and methods of identifying the same
DE59901930D1 (en) EXPRESSION SYSTEM FOR THE PRODUCTION OF PROTEINS
WO2000002912A3 (en) Disintegrin homologs
WO1997031612A3 (en) Mammalian endonuclease iii, and diagnostic and therapeutic uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2368998

Country of ref document: CA

Ref country code: CA

Ref document number: 2368998

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 608767

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000919948

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000919948

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09937837

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: 2000919948

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000919948

Country of ref document: EP